Literature DB >> 26628108

CREB-binding protein regulates lung cancer growth by targeting MAPK and CPSF4 signaling pathway.

Zhipeng Tang1, Wendan Yu1, Changlin Zhang2, Shilei Zhao1, Zhenlong Yu1, Xiangsheng Xiao2, Ranran Tang1, Yang Xuan1, Wenjing Yang1, Jiaojiao Hao1, Tingting Xu1, Qianyi Zhang1, Wenlin Huang3, Wuguo Deng4, Wei Guo5.   

Abstract

CBP (CREB-binding protein) is a transcriptional co-activator which possesses HAT (histone acetyltransferases) activity and participates in many biological processes, including embryonic development, growth control and homeostasis. However, its roles and the underlying mechanisms in the regulation of carcinogenesis and tumor development remain largely unknown. Here we investigated the molecular mechanisms and potential targets of CBP involved in tumor growth and survival in lung cancer cells. Elevated expression of CBP was detected in lung cancer cells and tumor tissues compared to the normal lung cells and tissues. Knockdown of CBP by siRNA or inhibition of its HAT activity using specific chemical inhibitor effectively suppressed cell proliferation, migration and colony formation and induced apoptosis in lung cancer cells by inhibiting MAPK and activating cytochrome C/caspase-dependent signaling pathways. Co-immunoprecipitation and immunofluorescence analyses revealed the co-localization and interaction between CBP and CPSF4 (cleavage and polyadenylation specific factor 4) proteins in lung cancer cells. Knockdown of CPSF4 inhibited hTERT transcription and cell growth induced by CBP, and vice versa, demonstrating the synergetic effect of CBP and CPSF4 in the regulation of lung cancer cell growth and survival. Moreover, we found that high expression of both CBP and CPSF4 predicted a poor prognosis in the patients with lung adenocarcinomas. Collectively, our results indicate that CBP regulates lung cancer growth by targeting MAPK and CPSF4 signaling pathways.
Copyright © 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CBP; CPSF4; Lung cancer; hTERT

Mesh:

Substances:

Year:  2015        PMID: 26628108      PMCID: PMC5528962          DOI: 10.1016/j.molonc.2015.10.015

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  48 in total

1.  CPSF4 activates telomerase reverse transcriptase and predicts poor prognosis in human lung adenocarcinomas.

Authors:  Wangbing Chen; Lijun Qin; Shusen Wang; Mei Li; Dingbo Shi; Yun Tian; Jingshu Wang; Lingyi Fu; Zhenglin Li; Wei Guo; Wendan Yu; Yuhui Yuan; Tiebang Kang; Wenlin Huang; Wuguo Deng
Journal:  Mol Oncol       Date:  2014-02-14       Impact factor: 6.603

Review 2.  Diagnosis and predictive molecular analysis of non-small-cell lung cancer in the Africa-Middle East region: challenges and strategies for improvement.

Authors:  Tomas Slavik; Fatima Asselah; Najla Fakhruddin; Ahmed El Khodary; Fairouz Torjman; Elia Anis; Martin Quinn; Azzam Khankan; Keith M Kerr
Journal:  Clin Lung Cancer       Date:  2014-06-21       Impact factor: 4.785

3.  HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas.

Authors:  Michael J Gray; Jing Zhang; Lee M Ellis; Gregg L Semenza; Douglas B Evans; Stephanie S Watowich; Gary E Gallick
Journal:  Oncogene       Date:  2005-04-28       Impact factor: 9.867

Review 4.  Lung cancer stem cells: progress and prospects.

Authors:  Amber Lundin; Barbara Driscoll
Journal:  Cancer Lett       Date:  2012-08-17       Impact factor: 8.679

5.  Thymine DNA glycosylase promotes transactivation of β-catenin/TCFs by cooperating with CBP.

Authors:  Yingying Jia; Fen Nie; Aiying Du; Zhangcheng Chen; Yuanbo Qin; Tao Huang; Xiaomin Song; Lin Li
Journal:  J Mol Cell Biol       Date:  2014-04-18       Impact factor: 6.216

6.  Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3'end formation of cellular pre-mRNAs.

Authors:  M E Nemeroff; S M Barabino; Y Li; W Keller; R M Krug
Journal:  Mol Cell       Date:  1998-06       Impact factor: 17.970

7.  The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia.

Authors:  G Giotopoulos; W-I Chan; S J Horton; D Ruau; P Gallipoli; A Fowler; C Crawley; E Papaemmanuil; P J Campbell; B Göttgens; J M Van Deursen; P A Cole; B J P Huntly
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

8.  Ku80 cooperates with CBP to promote COX-2 expression and tumor growth.

Authors:  Yao Xiao; Jingshu Wang; Yu Qin; Yang Xuan; Yunlu Jia; Wenxian Hu; Wendan Yu; Meng Dai; Zhenglin Li; Canhui Yi; Shilei Zhao; Mei Li; Sha Du; Wei Cheng; Xiangsheng Xiao; Yiming Chen; Taihua Wu; Songshu Meng; Yuhui Yuan; Quentin Liu; Wenlin Huang; Wei Guo; Shusen Wang; Wuguo Deng
Journal:  Oncotarget       Date:  2015-04-10

9.  Transcriptional coactivator CBP upregulates hTERT expression and tumor growth and predicts poor prognosis in human lung cancers.

Authors:  Wei Guo; Jianjun Lu; Meng Dai; Taihua Wu; Zhenlong Yu; Jingshu Wang; Wangbing Chen; Dingbo Shi; Wendan Yu; Yao Xiao; Canhui Yi; Zhipeng Tang; Tingting Xu; Xiangsheng Xiao; Yuhui Yuan; Quentin Liu; Guangwei Du; Wuguo Deng
Journal:  Oncotarget       Date:  2014-10-15

10.  [Expression and significance of Raf kinase inhibitory protein in lung cancer].

Authors:  Dayun Yang; Zhan Qi
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2012-10
View more
  10 in total

1.  CREB-binding protein regulates lung cancer growth by targeting MAPK and CPSF4 signaling pathway.

Authors:  Zhipeng Tang; Wendan Yu; Changlin Zhang; Shilei Zhao; Zhenlong Yu; Xiangsheng Xiao; Ranran Tang; Yang Xuan; Wenjing Yang; Jiaojiao Hao; Tingting Xu; Qianyi Zhang; Wenlin Huang; Wuguo Deng; Wei Guo
Journal:  Mol Oncol       Date:  2015-11-05       Impact factor: 6.603

2.  Pharmacological targeting of CBP/p300 drives a redox/autophagy axis leading to senescence-induced growth arrest in non-small cell lung cancer cells.

Authors:  Mohammad Salik Zeya Ansari; Venturina Stagni; Angela Iuzzolino; Dante Rotili; Antonello Mai; Donatella Del Bufalo; Patrizia Lavia; Francesca Degrassi; Daniela Trisciuoglio
Journal:  Cancer Gene Ther       Date:  2022-09-18       Impact factor: 5.854

3.  Repression of GCN5 expression or activity attenuates c-MYC expression in non-small cell lung cancer.

Authors:  Lisa Maria Mustachio; Jason Roszik; Aimee T Farria; Karla Guerra; Sharon Yr Dent
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

4.  lncRNA PLAC2 activated by H3K27 acetylation promotes cell proliferation and invasion via the activation of Wnt/β‑catenin pathway in oral squamous cell carcinoma.

Authors:  Fubo Chen; Shengcai Qi; Xu Zhang; Jinjin Wu; Xi Yang; Raorao Wang
Journal:  Int J Oncol       Date:  2019-02-01       Impact factor: 5.650

5.  A CRISPR Interference of CBP and p300 Selectively Induced Synthetic Lethality in Bladder Cancer Cells In Vitro.

Authors:  Jianfa Li; ChenChen Huang; Tiefu Xiong; Changshui Zhuang; Chengle Zhuang; Yawen Li; Jing Ye; Yaoting Gui
Journal:  Int J Biol Sci       Date:  2019-05-11       Impact factor: 6.580

6.  Interpreting Functional Impact of Genetic Variations by Network QTL for Genotype-Phenotype Association Study.

Authors:  Kai Yuan; Tao Zeng; Luonan Chen
Journal:  Front Cell Dev Biol       Date:  2022-01-26

7.  Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy.

Authors:  Adam Hermawan; Herwandhani Putri
Journal:  BMC Genom Data       Date:  2022-09-16

8.  Identification of consistent post-translational regulatory triplets related to oncogenic and tumour suppressive modulators in childhood acute lymphoblastic leukemia.

Authors:  YongKiat Wee; Yining Liu; Min Zhao
Journal:  PeerJ       Date:  2021-07-14       Impact factor: 2.984

9.  Epigenetic modifications promote the expression of the orphan nuclear receptor NR0B1 in human lung adenocarcinoma cells.

Authors:  Yongjie Lu; Yunqiang Liu; Shunyao Liao; Wenling Tu; Ying Shen; Yuanlong Yan; Dachang Tao; Yilu Lu; Yongxin Ma; Yuan Yang; Sizhong Zhang
Journal:  Oncotarget       Date:  2016-07-12

10.  The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancer.

Authors:  Shuo Wang; Bethany Woodvine; Vincent van Hoef; Cedric Darini; Nour Ghaddar; Jothilatha Krishnamoorthy; Urszula Kazimierczak; Nicolas Ah-Son; Helmuth Popper; Myriam Johnson; Leah Officer; Ana Teodósio; Massimo Broggini; Koren K Mann; Maria Hatzoglou; Ivan Topisirovic; Ola Larsson; John Le Quesne; Antonis E Koromilas
Journal:  Nat Commun       Date:  2021-07-30       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.